secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001823239-21-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q3 revenue up 133% to $204.8M; raises 2021 guidance, provides 2022 outlook
--------------------------------------------------------------------------------

- Q3 revenue $204.8M (+133% YoY); net income $132.8M (+240%); Adj EBITDA $156.0M.
- Nucleic Acid Production revenue $182.9M (+170% YoY) on demand for CleanCap mRNA vaccine components.
- 2021 guidance raised: revenue $770-780M, Adj EBITDA $570-575M, Adj diluted EPS $1.48-$1.52.
- Initial 2022 revenue guidance $840-880M, representing ~11-14% growth at midpoint after adjusting for divestiture.
- Completed sale of Protein Detection business; published inaugural ESG report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323921000025/0001823239-21-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323921000025/mrvi-20211110.htm
  HTML page:      https://secwatch.observer/filing/0001823239-21-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer